SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-19-040377
Filing Date
2019-11-05
Accepted
2019-11-05 16:10:42
Documents
5
Period of Report
2019-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K prnb-8k_20191104.htm 8-K 36012
2 EX-14.1 prnb-ex141_7.htm EX-14.1 150126
3 EX-99.1 prnb-ex991_8.htm EX-99.1 74835
4 GRAPHIC gdeypofrnsq4000001.jpg GRAPHIC 4729
5 GRAPHIC gtitimyi52o1000001.jpg GRAPHIC 55546
  Complete submission text file 0001564590-19-040377.txt   345486
Mailing Address 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080
Business Address 400 EAST JAMIE COURT, SUITE 302 SOUTH SAN FRANCISCO CA 94080 (650) 416-7700
Principia Biopharma Inc. (Filer) CIK: 0001510487 (see all company filings)

IRS No.: 263487603 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38653 | Film No.: 191193391
SIC: 2834 Pharmaceutical Preparations